Abstract
Obesity/diabetes is a major comorbidity in people with hypertension, and they often share the common pathological backgrounds, such as insulin resistance and vascular failure, and the risk of cardiovascular disease (CVD). Thus, obesity/diabetes is an essential culprit to hamper cardiometabolic health. One of the biggest highlights of recent years in the area or obesity/diabetes has been the remarkable benefits of newer glucose-lowering agents seen in the large-scale clinical trials on cardiorenal outcomes, followed by the relevant clinical guidelines update and the expansion of the clinical application of those agents. In addition, such agents with evidence proved to have common and incidental actions, such as body weight loss and blood pressure reduction, potentially contributing to the better management of risk factors. These evidence and insights have led to new trends in our clinical practice for obesity/diabetes and cardiometabolic syndrome. In this talk, we would like to introduce the progress of obesity/diabetes in area of Hypertension Research 2021 and their clinical perspectives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
